| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 259 | 2022 |
| Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients K Gowin, P Thapaliya, J Samuelson, C Harrison, D Radia, B Andreasson, ... haematologica 97 (10), 1570, 2012 | 104 | 2012 |
| Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research J Huberty, R Eckert, A Dueck, H Kosiorek, L Larkey, K Gowin, R Mesa BMC complementary and alternative medicine 19, 1-12, 2019 | 72 | 2019 |
| Survival following allogeneic transplant in patients with myelofibrosis K Gowin, K Ballen, KW Ahn, ZH Hu, H Ali, MO Arcasoy, R Devlin, ... Blood advances 4 (9), 1965-1973, 2020 | 71 | 2020 |
| Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis K Gowin, H Kosiorek, A Dueck, J Mascarenhas, R Hoffman, C Reeder, ... Leukemia Research 60, 31-35, 2017 | 42 | 2017 |
| Pegylated interferon alpha–2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial K Gowin, T Jain, H Kosiorek, R Tibes, J Camoriano, J Palmer, R Mesa Leukemia research 54, 73-77, 2017 | 40 | 2017 |
| Perceptions of myeloproliferative neoplasm patients participating in an online yoga intervention: a qualitative study J Huberty, R Eckert, L Larkey, K Gowin, J Mitchell, R Mesa Integrative cancer therapies 17 (4), 1150-1162, 2018 | 36 | 2018 |
| Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms J Huberty, R Eckert, K Gowin, J Mitchell, AC Dueck, BF Ginos, L Larkey, ... Haematologica 102 (10), e384, 2017 | 36 | 2017 |
| Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment K Gowin, S Skerget, JJ Keats, J Mikhael, AJ Cowan Leukemia Research 111, 106687, 2021 | 27 | 2021 |
| Physical activity as a nonpharmacological symptom management approach in myeloproliferative neoplasms: recommendations for future research R Eckert, J Huberty, K Gowin, R Mesa, L Marks Integrative cancer therapies 16 (4), 439-450, 2017 | 26 | 2017 |
| Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis K Gowin, M Coakley, H Kosiorek, R Mesa Haematologica 101 (10), e405, 2016 | 25 | 2016 |
| Understanding the mechanisms of diet and outcomes in colon, prostate, and breast cancer; malignant gliomas; and cancer patients on immunotherapy S Mann DO, M Sidhu DO, K Gowin DO Nutrients 12 (8), 2226, 2020 | 22 | 2020 |
| Final analysis of a multicenter pilot phase 2 study of ruxolitinib and danazol in patients with myelofibrosis KL Gowin, HE Kosiorek, AC Dueck, J Mascarenhas, R Hoffman, ... Blood 126 (23), 1618, 2015 | 15 | 2015 |
| The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms K Gowin, BT Langlais, HE Kosiorek, A Dueck, D Millstine, J Huberty, ... Cancer medicine 9 (24), 9445-9453, 2020 | 14 | 2020 |
| The new landscape of therapy for myelofibrosis K Gowin, R Emanuel, H Geyer, RA Mesa Current hematologic malignancy reports 8, 325-332, 2013 | 13 | 2013 |
| Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis K Gowin, R Mesa Expert opinion on investigational drugs 22 (12), 1603-1611, 2013 | 13 | 2013 |
| Profile of pomalidomide and its potential in the treatment of myelofibrosis KL Gowin, RA Mesa Therapeutics and Clinical Risk Management, 549-556, 2015 | 9 | 2015 |
| Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis K Menghrajani, PS Boonstra, JA Mercer, C Perkins, KL Gowin, AA Weber, ... Leukemia & lymphoma 60 (4), 1036-1042, 2019 | 8 | 2019 |
| Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis J Perram, DM Ross, D McLornan, K Gowin, N Kröger, V Gupta, C Lewis, ... American Journal of Hematology 97 (11), 1464-1477, 2022 | 7 | 2022 |
| Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis K Gowin, S Verstovsek, N Daver, N Pemmaraju, R Valdez, H Kosiorek, ... Leukemia research 39 (7), 684-688, 2015 | 7 | 2015 |
